PNEUMOVAX 23 is a vaccine given to help prevent infections caused by certain types of germs or bacteria called pneumococcus (pronounced new-mo-kock-us). For more information, see Section 1.

In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.

Dominance of the pneumococcal vaccine category is a race between Merck ... Merck also sells an older shot called Pneumovax 23, which covers 23 serotypes but is based on an older polysaccharide ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both ...